About ASN

Catherine serves as chief executive officer and as a board member of Winnow Therapeutics since December 1015. Previously she served as the CEO of Chroma Medicine until its merger with Nvelop in December 2024. Prior to that, she was the entrepreneur-in-residence at Atlas Venture, serving as the chief medical officer of both Dyne Therapeutics and Disarm Therapeutics. She also spent time as the chief medical officer of Sarepta Therapeutics and as the vice president, clinical development and regulatory affairs at Regeneron Pharmaceuticals, initially as the head, pain therapeutic areas, and subsequently as the head, clinical project management and operations. From 2003 to 2015, she held senior leadership roles at Amgen, including as the vice president, global development, leading the neuroscience, nephrology, and bone therapeutic areas. Catherine earned her MD from the University of Chicago in 1990. She conducted her residency and fellowship training at the University of Washington, where she also received a Master of Science degree in epidemiology in 1996. From 1997 to 2003, Catherine was a faculty member in the Division of Nephrology at the University of Washington, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in patients with kidney disease. Catherine was also active in various national programs, including serving as the chair for the United States Renal Data System National Institute of Diabetes and Digestive and Kidney Diseases external expert panel and a reviewer for several journals.